Glenmark Pharmaceuticals Limited has informed the Exchange about ESG Rating.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals has disclosed that SES ESG Research Private Limited has assigned it an ESG rating of 71.1 for FY 2025. The rating was communicated via email dated January 4, 2026. Importantly, the company clarified that it did not engage or commission SES ESG for this rating — the agency assigned it independently based on publicly available information. The disclosure is being made under SEBI's Listing Regulations. An ESG score of 71.1 is generally considered strong and reflects above-average performance on environmental, social, and governance parameters.
A solid independent ESG rating of 71.1 can be mildly positive for investor perception, especially attracting ESG-focused funds, but since the company did not commission the rating, it is likely a one-time informational disclosure with limited direct impact on stock price or operations.